Novel bladder preservation therapy for locally invasive bladder cancer: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation

Haruhito Azuma, Teruo Inamoto, Naokazu Ibuki, Takanobu Ubai, Yatsugu Kotake, Kiyoshi Takahara, Satoshi Kiyama, Hayahito Nomi, Hiroshi Uehara, Kazumasa Komura, Kazuhiro Yamamoto, Yoshihumi Narumi, Yoji Katsuoka

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We investigated the effect of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), used concomitantly with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation (referred to as the OMC-regimen) in patients with advanced bladder cancer. One hundred and ninety-two patients were assigned to receive either the OMC-regimen (n=96) or total cystectomy (n=96). Patients in the OMC-regimen group who failed to achieve CR underwent cystectomy, or secondary BOAI with an increased amount of CDDP or gemcitabine (1600 mg). The OMC-regimen allowed >89% (69/77) of patients with locally invasive tumors to achieve CR [>70% (70/96) of all patients including those with T4 and N(+) disease]. Most (68/69) of the CR patients were still alive with no evidence of recurrence after a mean follow-up of 161 (range 12-805) weeks. The 5- and 15-year overall survival rates were 91.5 and 81.3% (vs. 59.8% and 40.1% for cystectomy, P<0.0001), respectively. No patients suffered Grade III or more severe toxicities. In contrast, at 5 and 15 years after surgery in the total cystectomy group, about 50 and 60% of patients had suffered disease progression or had died, respectively. The OMC-regimen, a new bladder-preservation strategy for patients with locally invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative therapy would otherwise seem the only option.

Original languageEnglish
Pages (from-to)773-785
Number of pages13
JournalInternational Journal of Oncology
Volume37
Issue number4
DOIs
Publication statusPublished - 01-10-2010

Fingerprint

Urinary Bladder Neoplasms
Antineoplastic Agents
Renal Dialysis
Urinary Bladder
Radiation
Cystectomy
gemcitabine
Therapeutics
Palliative Care
Cisplatin
Disease Progression
Neoplasms
Survival Rate
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Azuma, Haruhito ; Inamoto, Teruo ; Ibuki, Naokazu ; Ubai, Takanobu ; Kotake, Yatsugu ; Takahara, Kiyoshi ; Kiyama, Satoshi ; Nomi, Hayahito ; Uehara, Hiroshi ; Komura, Kazumasa ; Yamamoto, Kazuhiro ; Narumi, Yoshihumi ; Katsuoka, Yoji. / Novel bladder preservation therapy for locally invasive bladder cancer : Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. In: International Journal of Oncology. 2010 ; Vol. 37, No. 4. pp. 773-785.
@article{acb18891e97a4cc5973cdc8e2c7bb3cf,
title = "Novel bladder preservation therapy for locally invasive bladder cancer: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation",
abstract = "We investigated the effect of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), used concomitantly with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation (referred to as the OMC-regimen) in patients with advanced bladder cancer. One hundred and ninety-two patients were assigned to receive either the OMC-regimen (n=96) or total cystectomy (n=96). Patients in the OMC-regimen group who failed to achieve CR underwent cystectomy, or secondary BOAI with an increased amount of CDDP or gemcitabine (1600 mg). The OMC-regimen allowed >89{\%} (69/77) of patients with locally invasive tumors to achieve CR [>70{\%} (70/96) of all patients including those with T4 and N(+) disease]. Most (68/69) of the CR patients were still alive with no evidence of recurrence after a mean follow-up of 161 (range 12-805) weeks. The 5- and 15-year overall survival rates were 91.5 and 81.3{\%} (vs. 59.8{\%} and 40.1{\%} for cystectomy, P<0.0001), respectively. No patients suffered Grade III or more severe toxicities. In contrast, at 5 and 15 years after surgery in the total cystectomy group, about 50 and 60{\%} of patients had suffered disease progression or had died, respectively. The OMC-regimen, a new bladder-preservation strategy for patients with locally invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative therapy would otherwise seem the only option.",
author = "Haruhito Azuma and Teruo Inamoto and Naokazu Ibuki and Takanobu Ubai and Yatsugu Kotake and Kiyoshi Takahara and Satoshi Kiyama and Hayahito Nomi and Hiroshi Uehara and Kazumasa Komura and Kazuhiro Yamamoto and Yoshihumi Narumi and Yoji Katsuoka",
year = "2010",
month = "10",
day = "1",
doi = "10.3892/ijo-00000727",
language = "English",
volume = "37",
pages = "773--785",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

Novel bladder preservation therapy for locally invasive bladder cancer : Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. / Azuma, Haruhito; Inamoto, Teruo; Ibuki, Naokazu; Ubai, Takanobu; Kotake, Yatsugu; Takahara, Kiyoshi; Kiyama, Satoshi; Nomi, Hayahito; Uehara, Hiroshi; Komura, Kazumasa; Yamamoto, Kazuhiro; Narumi, Yoshihumi; Katsuoka, Yoji.

In: International Journal of Oncology, Vol. 37, No. 4, 01.10.2010, p. 773-785.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel bladder preservation therapy for locally invasive bladder cancer

T2 - Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation

AU - Azuma, Haruhito

AU - Inamoto, Teruo

AU - Ibuki, Naokazu

AU - Ubai, Takanobu

AU - Kotake, Yatsugu

AU - Takahara, Kiyoshi

AU - Kiyama, Satoshi

AU - Nomi, Hayahito

AU - Uehara, Hiroshi

AU - Komura, Kazumasa

AU - Yamamoto, Kazuhiro

AU - Narumi, Yoshihumi

AU - Katsuoka, Yoji

PY - 2010/10/1

Y1 - 2010/10/1

N2 - We investigated the effect of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), used concomitantly with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation (referred to as the OMC-regimen) in patients with advanced bladder cancer. One hundred and ninety-two patients were assigned to receive either the OMC-regimen (n=96) or total cystectomy (n=96). Patients in the OMC-regimen group who failed to achieve CR underwent cystectomy, or secondary BOAI with an increased amount of CDDP or gemcitabine (1600 mg). The OMC-regimen allowed >89% (69/77) of patients with locally invasive tumors to achieve CR [>70% (70/96) of all patients including those with T4 and N(+) disease]. Most (68/69) of the CR patients were still alive with no evidence of recurrence after a mean follow-up of 161 (range 12-805) weeks. The 5- and 15-year overall survival rates were 91.5 and 81.3% (vs. 59.8% and 40.1% for cystectomy, P<0.0001), respectively. No patients suffered Grade III or more severe toxicities. In contrast, at 5 and 15 years after surgery in the total cystectomy group, about 50 and 60% of patients had suffered disease progression or had died, respectively. The OMC-regimen, a new bladder-preservation strategy for patients with locally invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative therapy would otherwise seem the only option.

AB - We investigated the effect of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), used concomitantly with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation (referred to as the OMC-regimen) in patients with advanced bladder cancer. One hundred and ninety-two patients were assigned to receive either the OMC-regimen (n=96) or total cystectomy (n=96). Patients in the OMC-regimen group who failed to achieve CR underwent cystectomy, or secondary BOAI with an increased amount of CDDP or gemcitabine (1600 mg). The OMC-regimen allowed >89% (69/77) of patients with locally invasive tumors to achieve CR [>70% (70/96) of all patients including those with T4 and N(+) disease]. Most (68/69) of the CR patients were still alive with no evidence of recurrence after a mean follow-up of 161 (range 12-805) weeks. The 5- and 15-year overall survival rates were 91.5 and 81.3% (vs. 59.8% and 40.1% for cystectomy, P<0.0001), respectively. No patients suffered Grade III or more severe toxicities. In contrast, at 5 and 15 years after surgery in the total cystectomy group, about 50 and 60% of patients had suffered disease progression or had died, respectively. The OMC-regimen, a new bladder-preservation strategy for patients with locally invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative therapy would otherwise seem the only option.

UR - http://www.scopus.com/inward/record.url?scp=77956499362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956499362&partnerID=8YFLogxK

U2 - 10.3892/ijo-00000727

DO - 10.3892/ijo-00000727

M3 - Article

C2 - 20811698

AN - SCOPUS:77956499362

VL - 37

SP - 773

EP - 785

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -